A Multicenter, Open Label Single Arm Phase II Study to Evaluate the Effect and Safety Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer
Latest Information Update: 21 Feb 2022
At a glance
- Drugs Disitamab vedotin (Primary) ; Fruquintinib (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 21 Feb 2022 New trial record